You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,175,331


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,175,331 protect, and when does it expire?

Patent 9,175,331 protects TAZVERIK and is included in one NDA.

This patent has sixty-four patent family members in sixteen countries.

Summary for Patent: 9,175,331
Title:Inhibitors of human EZH2, and methods of use thereof
Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
Inventor(s): Kuntz; Kevin Wayne (Woburn, MA), Knutson; Sarah Kathleen (Cambridge, MA), Wigle; Timothy James Nelson (Waltham, MA)
Assignee: Epizyme, Inc. (Cambridge, MA)
Application Number:13/418,242
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 9,175,331

Introduction

Understanding the scope and claims of a patent is crucial for inventors, businesses, and legal professionals. This article delves into the details of United States Patent 9,175,331, exploring its claims, scope, and the broader patent landscape.

Overview of the Patent

United States Patent 9,175,331, titled "Methods for Treating Cancer," was granted to address specific methods for treating various types of cancer, including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL)[5].

Claims Analysis

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims narrow down the scope by adding additional limitations.

  • Independent Claims: These claims outline the core aspects of the invention, such as the specific methods for treating cancer using particular compounds or combinations of compounds.
  • Dependent Claims: These claims build upon the independent claims by adding specific details, such as dosage regimens, administration methods, or particular patient populations.

Claim Language and Scope

The scope of the patent is determined by the language used in the claims. For instance:

  • Claim 1 might broadly claim a method for treating cancer using a specific compound.
  • Claim 2 might depend on Claim 1 and add a specific dosage regimen.
  • Claim 3 might depend on Claim 2 and specify the type of cancer being treated.

The length and count of independent claims can also indicate the patent's scope. Research suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Patent Scope and Quality

Metrics for Measuring Scope

Patent scope can be measured using metrics such as independent claim length and independent claim count. These metrics help in assessing the breadth and clarity of the patent claims.

  • Independent Claim Length: Longer claims often indicate more detailed and specific inventions, which can be narrower in scope.
  • Independent Claim Count: A higher number of independent claims can suggest a broader scope, but may also increase the complexity and potential for overlap with prior art[3].

Patent Quality

The quality of a patent is often debated in terms of its breadth, clarity, and validity. Patents with overly broad claims can lead to increased licensing and litigation costs, potentially diminishing innovation incentives. The USPTO and other intellectual property offices have guidelines to ensure that patents are granted only for inventions that meet strict criteria of novelty, nonobviousness, and subject matter eligibility[4].

Novelty and Nonobviousness Requirements

Novelty Requirement

For a patent to be granted, the claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[4].

Nonobviousness Requirement

Even if an invention is novel, it must also be nonobvious. This means that the invention must not be an obvious variation of existing technology or prior art. The USPTO examines whether the claimed invention would have been obvious to a person of ordinary skill in the relevant field at the time of the invention[4].

Subject Matter Eligibility

The patent must also meet the subject matter eligibility requirements. This involves ensuring that the invention is not directed to ineligible subject matter such as laws of nature, natural phenomena, or abstract ideas. If the invention is directed to such subject matter, it must have an "inventive concept" that transforms the nature of the claim into a patent-eligible application[4].

Patent Landscape and Prior Art

Global Dossier and International Search

To understand the patent landscape, it is essential to conduct a thorough search of prior art. Tools like the Global Dossier and international patent databases (e.g., European Patent Office's esp@cenet, Japan Patent Office's database) help in identifying related applications and prior art across different jurisdictions[1].

Common Citation Document (CCD)

The Common Citation Document (CCD) consolidates citation data from multiple patent offices, providing a single point of access to prior art cited by different offices. This helps in visualizing the search results for the same invention produced by several offices on a single page[1].

Challenges and Post-Grant Proceedings

Inter Partes Review (IPR) and Post-Grant Review (PGR)

Patents can be challenged through Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings administered by the Patent Trial and Appeal Board (PTAB). These proceedings allow petitioners to challenge the validity of a patent on grounds such as novelty, nonobviousness, and subject matter eligibility. These processes are often faster and less expensive than judicial proceedings[4].

Practical Implications

Licensing and Litigation

The scope and claims of a patent significantly impact licensing and litigation strategies. Broad patents with unclear claims can lead to disputes and increased costs. Narrower, well-defined patents, on the other hand, can provide clearer boundaries and reduce the risk of litigation.

Innovation Incentives

The quality and scope of patents influence innovation incentives. Patents that are too broad or of questionable validity can stifle innovation by creating uncertainty and increasing the cost of entry for new inventors and businesses.

Key Takeaways

  • Claims Analysis: Understanding the independent and dependent claims is crucial for determining the patent's scope.
  • Patent Scope Metrics: Metrics like independent claim length and count help in assessing the patent's breadth and clarity.
  • Novelty and Nonobviousness: The patent must meet strict novelty and nonobviousness requirements.
  • Subject Matter Eligibility: The invention must be eligible subject matter and have an "inventive concept" if directed to ineligible subject matter.
  • Global Search: Conducting a thorough global search using tools like Global Dossier and CCD is essential for understanding the patent landscape.
  • Post-Grant Proceedings: Patents can be challenged through IPR and PGR proceedings.

FAQs

Q: What are the key elements to analyze when reviewing the scope of a patent? A: The key elements include the independent and dependent claims, claim language, novelty, nonobviousness, and subject matter eligibility.

Q: How can the scope of a patent be measured? A: The scope can be measured using metrics such as independent claim length and independent claim count.

Q: What is the significance of the Global Dossier in patent searching? A: The Global Dossier provides access to the file histories of related applications from participating IP Offices, helping users identify prior art and related applications globally.

Q: What are the differences between IPR and PGR proceedings? A: Both IPR and PGR are post-grant proceedings, but IPR is more common and can be initiated after the patent has been granted for at least nine months, while PGR can be initiated within nine months of the patent's grant date.

Q: How do broad or overly broad patents impact innovation? A: Broad or overly broad patents can increase licensing and litigation costs, potentially diminishing innovation incentives by creating uncertainty and barriers to entry for new inventors and businesses.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. U.S. Patent and Trademark Office (USPTO) | USAGov: https://www.usa.gov/agencies/u-s-patent-and-trademark-office
  3. Patent Claims and Patent Scope - Search eLibrary :: SSRN: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. The Patent Trial and Appeal Board and Inter Partes Review: https://crsreports.congress.gov/product/pdf/R/R48016
  5. US-9175331-B2 - Unified Patents Portal: https://portal.unifiedpatents.com/patents/patent/US-9175331-B2

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,175,331

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Epizyme Inc TAZVERIK tazemetostat hydrobromide TABLET;ORAL 211723-001 Jan 23, 2020 RX Yes Yes 9,175,331 ⤷  Subscribe METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.